Neurelis

Executive Summary

Neurelis is a neuroscience-focused pharmaceutical company dedicated to developing and commercializing innovative therapies for neurological conditions, with a particular emphasis on advanced drug delivery technologies. Founded in 2007 and headquartered in San Diego, the company aims to empower patients and healthcare providers by enhancing treatment options for conditions such as epilepsy, Parkinson's disease, and other central nervous system disorders. Neurelis leverages its proprietary formulation and delivery platforms to improve the efficacy, safety, and convenience of neurological therapeutics, addressing unmet needs in acute and chronic care settings. As a private company, Neurelis continues to advance its pipeline of product candidates targeting seizure clusters and other neurological indications. The company's lead candidate utilizes its intranasal delivery technology, which offers rapid onset and ease of administration. Near-term catalysts include potential regulatory submissions or approvals, clinical trial readouts, and strategic partnerships that could expand the reach of its platform. With a strong focus on patient-centric innovation, Neurelis is positioned to drive meaningful advancements in neurology, though commercial success will depend on execution and market adoption.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Clinical Trial Results for Lead Intranasal Candidate65% success
• Q1 2027FDA Approval Decision for Expanded Indication55% success
• TBDStrategic Partnership or Licensing Deal for Drug Delivery Platform50% success